Graves ophthalmopathy(GO)is an extrathyroidal manifestation of Graves'disease,mainly a complexau-toimmune disease mediated by cellular immunity.Orbital fibroblasts and adipocytes are target cells for immune response,while Thyroid stimulating hormone receptor and insulin-like growth factor-1 are key autoantigens.In addition to smoking,post radiation iodine therapy,and other risk factors,hypercholesterolemia has been identified as a new risk factor for GO.Corticosteroids have an unshakable position in the treatment of moderate to severe active GO,but some patients do not re-spond after treatment or experience recurrence.It is necessary to seek new drugs.Bio-targeted agents,cytokine inhibitors,and statins with anti-inflammatory effects have gradually been studied and applied in the clinical treatment of GO.This re-view mainly introduces the main pathogenesis of GO and the new progress in drug therapy for moderate to severe active GO.
国家科技期刊平台
NSTL
维普
万方数据
